A migraine drug built on a modified tryptamine-like structure
In short: Naratriptan is a migraine medicine from the triptan family, a group of drugs that act on serotonin receptors. Its chemistry sits close to the psychedelic compound DMT, yet it is not technically a tryptamine. It was patented in 1987 and first reached patients in 1997, showing how deliberate structural changes can turn a familiar molecular framework into a targeted treatment.
Naratriptan, sold under brand names such as Amerge and Naramig, is a triptan used to treat acute migraine attacks. Migraine brings severe, throbbing headaches that can come with nausea and heightened sensitivity to sound or light. The drug acts as a selective agonist of the serotonin 5-HT1 receptor family, and that activity is believed to explain its effect, even though the underlying causes of migraine remain poorly understood.
The chemistry is an interesting story. Naratriptan is a modified analogue of tryptamines such as dimethyltryptamine. Rather than the ethylamine side chain found in tryptamines, it carries a 1-methylpiperidin-4-yl side chain. It also carries a substitution on the indole ring system and has a cyclized amine portion. Because of these changes, chemists classify it as a piperidinylindole rather than a tryptamine.
Clinical evidence gives a nuanced picture. A meta-analysis of 53 trials found that all triptans are effective at marketed doses. Naratriptan was less effective than sumatriptan and rizatriptan, yet it outperformed placebo in easing symptoms at two hours, and benefit was seen in roughly two thirds of patients after four hours. Its side effects resemble those of other triptans, including warmth, dizziness, drowsiness and tingling, and they were reported less often than with sumatriptan and rarely at doses above 2.5 mg.
Regulatory and market history also shaped access to the drug. The US Food and Drug Administration approved it on February 11, 1998, and its US patent was listed as expiring on July 7, 2010, after which several manufacturers launched generic versions. In Canada, a 2014 quarantine of imports from one Indian supplier, requested by Health Canada, placed generic naratriptan on the national drug shortage list, a reminder of how manufacturing supply chains affect patients.
Opens the Intellect+ feed with this card first. Swipe up for the next one.
Sources
- Summary by Intellect · source: Naratriptan
To cite this card, link to https://intellectplus.co.uk/app/health-naratriptan.
How we source, check and correct cards: Editorial standards.
General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.
Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?
Related
More in Health, medicine and disease · More in Health · Latest · A–Z · All topics